ALDH1 inhibition by DIMATE maintains immune responses and promotes immunogenic remodeling in AML
Acute myeloid leukemia (AML) treatments often cause profound immunosuppression, limiting immune-mediated control of residual disease. DIMATE, an ALDH1 inhibitor under clinical evaluation, induces aldehyde and redox stress in leukemic cells, but its impact on immune effector functions and tumor immunogenicity remains in...